Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics (GLYC)
NASDAQ:GLYC
Holding GLYC?
Track your performance easily
GLYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.14 - $3.53
Previous Close$0.23
Volume1.03M
Average Volume (3M)19.67M
Market Cap
$13.25M
Enterprise Value-$886.41K
Total Cash (Recent Filing)$14.40M
Total Debt (Recent Filing)$262.13K
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding64,483,958
10 Day Avg. Volume755,563
30 Day Avg. Volume19,669,284
Standard Deviation0.41
R-Squared0.05
Alpha-0.00550
Financial Highlights & Ratios
Price to Book (P/B)1.30
Price to Sales (P/S)1325.15
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-88.64
Enterprise Value/Gross Profit-88.64
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
GlycoMimetics News
PremiumCompany Announcements
GlycoMimetics and Crescent Biopharma Merger Advances
PremiumPre-Earnings
Is GLYC a Buy, Before Earnings?
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GLYC FAQ
What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $0.14 and its highest was $3.53 in the past 12 months.
What is GlycoMimetics’s market cap?
Currently, no data Available
When is GlycoMimetics’s upcoming earnings report date?
GlycoMimetics’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were GlycoMimetics’s earnings last quarter?
GlycoMimetics released its earnings results on Nov 07, 2024. The company reported -$0.152 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.042.
Is GlycoMimetics overvalued?
According to Wall Street analysts GlycoMimetics’s price is currently Overvalued.
Does GlycoMimetics pay dividends?
GlycoMimetics does not currently pay dividends.
What is GlycoMimetics’s EPS estimate?
GlycoMimetics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlycoMimetics have?
GlycoMimetics has 64,483,955 shares outstanding.
What happened to GlycoMimetics’s price movement after its last earnings report?
GlycoMimetics reported an EPS of -$0.152 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 10.526%.
Which hedge fund is a major shareholder of GlycoMimetics?
Currently, no hedge funds are holding shares in GLYC
---
GlycoMimetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GLYC Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 12.3%
Last 30 Days ▼ 12.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.63%
12-Months-Change
Fundamentals
Return on Equity
-137.20%
Trailing 12-Months
Asset Growth
-70.49%
Trailing 12-Months
Company Description
GlycoMimetics
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
---
GLYC Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed challenges with the Phase III trial not meeting its primary endpoint, leading to financial and strategic reassessments. However, there is a commitment to further analyze the rich data collected and ongoing trials continue to explore the potential of uproleselan in AML treatment.Read More>---
GLYC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
X4 Pharmaceuticals
―
Kazia Therapeutics
―
Corvus Pharmaceuticals
―
Best Analysts Covering GLYC
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-19.00%
reiterated a buy rating 9 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -19.00% per trade.
---